Revance to Participate in Upcoming Investor Conferences

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the company will participate in two upcoming investor conferences.

President and Chief Executive Officer, Dan Browne, is scheduled to present at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13 at 8:40am ET.

Chief Financial Officer and Chief Business Officer, Lauren Silvernail, is scheduled to participate in a fireside chat discussion at the Barclays Capital Healthcare Conference in Miami, FL on Thursday, March 15 at 8:00am ET.

Interested parties can access the live audio webcasts for both conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005219/en/

INVESTORS
Revance Therapeutics, Inc.
Jeanie Herbert, 714-325-3584
[email protected]
or
Burns McClellan, Inc.
Ami Bavishi, 212-213-0006
[email protected]
or
MEDIA
General Media:
TOGORUN
Mariann Caprino, 917-242-1087
[email protected]
or
Trade Media:
Nadine Tosk, 504-453-8344
[email protected]

Source: Revance Therapeutics, Inc.

You May Also Be Interested In

• Finland's Aalto Works joins the UNESCO World Heritage List, with five sites in Helsinki
• 2026 World Internet Conference Digital Silk Road Development Forum Opens in Xi'an, Shaanxi Province
• Meridian Holdings to Announce Second Quarter 2026 Financial Results